We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+2.29%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$1.1B
AUM Growth
+$93.7M
Cap. Flow
+$96.1M
Cap. Flow %
8.76%
Top 10 Hldgs %
40.44%
Holding
102
New
24
Increased
37
Reduced
19
Closed
19

Top Buys

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$22.3M
2
ABT icon
Abbott
ABT
+$15.9M
3
NTRA icon
Natera
NTRA
+$12.9M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$12.8M
5
MMSI icon
Merit Medical Systems
MMSI
+$12.7M

Top Sells

Rank Stock Value
1
ADMA icon
ADMA Biologics
ADMA
+$23.2M
2
MDT icon
Medtronic
MDT
+$20.5M
3
MRK icon
Merck
MRK
+$19.8M
4
CNC icon
Centene
CNC
+$18.9M
5
UTHR icon
United Therapeutics
UTHR
+$13.9M

Sector Composition

Rank Sector Weight
1 Healthcare 85.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COO icon
26
Cooper Companies
COO
$13.7B
$12.1M 1.11%
169,829
+69,027
+68% +$5.46M
NTRA icon
27
Natera
NTRA
$37.9B
$12M 1.09%
+60,004
New +$12.9M
ITGR icon
28
Integer Holdings
ITGR
$3.29B
$11.9M 1.08%
135,081
+28,496
+27% +$2.43M
RYTM icon
29
Rhythm Pharmaceuticals
RYTM
$7.14B
$11.9M 1.08%
136,621
+96,411
+240% +$9.38M
WAT icon
30
Waters Corp
WAT
$36.3B
$11.8M 1.08%
39,763
-3,445
-8% -$1.18M
AMRX icon
31
Amneal Pharmaceuticals
AMRX
$5.75B
$11.6M 1.05%
930,096
-535,384
-37% -$7.19M
PRAX icon
32
Praxis Precision Medicines
PRAX
$8.67B
$11.4M 1.04%
35,438
+4,275
+14% +$1.32M
HSIC icon
33
Henry Schein
HSIC
$9.67B
$11.3M 1.03%
+153,114
New +$11.8M
CGON icon
34
CG Oncology
CGON
$6.26B
$11.2M 1.02%
165,925
+1,958
+1% +$111K
MMSI icon
35
Merit Medical Systems
MMSI
$4.36B
$11.2M 1.02%
+162,469
New +$12.7M
CLDX icon
36
Celldex Therapeutics
CLDX
$2.66B
$10.3M 0.94%
324,957
+191,796
+144% +$5.23M
BLTE
37
Belite Bio
BLTE
$6.33B
$9.48M 0.86%
59,432
+39,609
+200% +$6.66M
DXCM icon
38
DexCom
DXCM
$27.9B
$9.4M 0.86%
149,734
-77,623
-34% -$5.41M
TERN
39
DELISTED
Terns Pharmaceuticals
TERN
$9.12M 0.83%
+172,962
New +$7.1M
CNC icon
40
Centene
CNC
$33B
$8.63M 0.79%
263,486
-461,938
-64% -$18.9M
VKTX icon
41
Viking Therapeutics
VKTX
$4.36B
$8.56M 0.78%
263,106
+74,150
+39% +$2.38M
ORKA
42
Oruka Therapeutics
ORKA
$5.68B
$8.54M 0.78%
+174,052
New +$6.05M
TNGX icon
43
Tango Therapeutics
TNGX
$4.63B
$8.5M 0.77%
+406,245
New +$5.65M
SLNO
44
DELISTED
Soleno Therapeutics
SLNO
$8.31M 0.76%
248,180
+287
+0.1% +$11.3K
BTSG icon
45
BrightSpring Health Services
BTSG
$14.1B
$7.98M 0.73%
187,335
+68,810
+58% +$2.77M
CMPS
46
Compass Pathways
CMPS
$1.64B
$7.56M 0.69%
1,367,099
+587,481
+75% +$3.95M
TMO icon
47
Thermo Fisher Scientific
TMO
$194B
$7.29M 0.66%
14,832
-23,083
-61% -$12.5M
NVO
48
Novo Nordisk
NVO
$215B
$7.25M 0.66%
+197,181
New +$9.34M
SYK icon
49
Stryker
SYK
$119B
$7.21M 0.66%
21,957
-28,895
-57% -$10.4M
VERA icon
50
Vera Therapeutics
VERA
$2.61B
$7.03M 0.64%
174,867
+67,177
+62% +$2.89M
1
2
3 4 5

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
CPRC
Consolidated Portfolio Review Corp Woodbury, New York $1.1B AUM 8.96% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.1B AUM 30.57% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return

PFM Health Sciences's Q1 2026 Portfolio in Review

As of Q1 2026, PFM Health Sciences held 102 positions worth $1.1B, up 9.3% from $1B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

PFM Health Sciences deployed $96.1M of net new capital in Q1 2026, opening 24 new positions and adding to 37 existing holdings. Its largest new stake was Abbott: 140,432 shares worth $14.4M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 97% a quarter earlier.

On the sell side, the largest reduction was Centene, an estimated $18.9M trimmed.

  • PFM Health Sciences's largest Q1 2026 buy was Abbott: 140,432 shares worth $14.4M.
  • PFM Health Sciences added most to Jazz Pharmaceuticals in Q1 2026, an estimated $22.3M increase.
  • PFM Health Sciences's biggest Q1 2026 reduction was Centene, cutting an estimated $18.9M.
  • PFM Health Sciences fully exited ADMA Biologics in Q1 2026, selling an estimated $23.2M.
  • PFM Health Sciences's ten largest holdings make up 40% of its $1.1B portfolio in Q1 2026.
  • PFM Health Sciences opened 24 new positions and closed 19 in Q1 2026.
  • PFM Health Sciences's portfolio value rose 9.3% quarter-over-quarter to $1.1B.

Based on PFM Health Sciences's 13F filing for Q1 2026, filed 15 May 2026.